drugset / Trial / NCT04655170
Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD
Phase 4
Recruiting
60 enrolled
University of Tennessee Graduate School of Medicine
Mylan Pharmaceuticals Inc · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized Albuterol and Ipratropium.
Timeline
- Start
- 2020-12-09
- Primary completion
- 2023-01-30
- Completion
- 2023-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Formoterol | Other / unclassified | 20 ug | Inhaled |
| Comparator | Ipratropium | Small molecule | — | Inhaled |
| Subject | Revefenacin | Small molecule | 175 ug | Inhaled |
| Comparator | Salbutamol | Unknown | — | Inhaled |